CN111642750A - 肾癌专用型临床营养配方食品及其制备方法 - Google Patents
肾癌专用型临床营养配方食品及其制备方法 Download PDFInfo
- Publication number
- CN111642750A CN111642750A CN202010538786.8A CN202010538786A CN111642750A CN 111642750 A CN111642750 A CN 111642750A CN 202010538786 A CN202010538786 A CN 202010538786A CN 111642750 A CN111642750 A CN 111642750A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- zinc
- kidney cancer
- selenium
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000008839 Kidney Neoplasms Diseases 0.000 title claims abstract description 51
- 206010038389 Renal cancer Diseases 0.000 title claims abstract description 48
- 201000010982 kidney cancer Diseases 0.000 title claims abstract description 48
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 38
- 235000013305 food Nutrition 0.000 title claims abstract description 26
- 230000035764 nutrition Effects 0.000 title claims description 18
- 238000002360 preparation method Methods 0.000 title abstract description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 54
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 44
- 239000002994 raw material Substances 0.000 claims description 29
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 26
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 24
- 229910052711 selenium Inorganic materials 0.000 claims description 24
- 239000011669 selenium Substances 0.000 claims description 24
- 229940091258 selenium supplement Drugs 0.000 claims description 24
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 22
- 241000251511 Holothuroidea Species 0.000 claims description 22
- 229960002949 fluorouracil Drugs 0.000 claims description 22
- 229930003427 Vitamin E Natural products 0.000 claims description 20
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 20
- 229940046009 vitamin E Drugs 0.000 claims description 20
- 235000019165 vitamin E Nutrition 0.000 claims description 20
- 239000011709 vitamin E Substances 0.000 claims description 20
- 229940045109 genistein Drugs 0.000 claims description 19
- 235000006539 genistein Nutrition 0.000 claims description 19
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 19
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 19
- 150000004676 glycans Chemical class 0.000 claims description 19
- 229920001282 polysaccharide Polymers 0.000 claims description 19
- 239000005017 polysaccharide Substances 0.000 claims description 19
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 claims description 18
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 claims description 18
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 claims description 18
- 239000011701 zinc Substances 0.000 claims description 18
- 229910052725 zinc Inorganic materials 0.000 claims description 18
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 17
- 229930003268 Vitamin C Natural products 0.000 claims description 17
- 239000003094 microcapsule Substances 0.000 claims description 17
- 235000019154 vitamin C Nutrition 0.000 claims description 17
- 239000011718 vitamin C Substances 0.000 claims description 17
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 15
- 239000001263 FEMA 3042 Substances 0.000 claims description 15
- 108010024636 Glutathione Proteins 0.000 claims description 15
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 15
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 15
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 15
- 235000021085 polyunsaturated fats Nutrition 0.000 claims description 15
- 229920002258 tannic acid Polymers 0.000 claims description 15
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 15
- 229940033123 tannic acid Drugs 0.000 claims description 15
- 235000015523 tannic acid Nutrition 0.000 claims description 15
- 229940045997 vitamin a Drugs 0.000 claims description 15
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 14
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 14
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 14
- 235000019155 vitamin A Nutrition 0.000 claims description 14
- 239000011719 vitamin A Substances 0.000 claims description 14
- 108010064851 Plant Proteins Proteins 0.000 claims description 13
- 235000021118 plant-derived protein Nutrition 0.000 claims description 13
- 244000241838 Lycium barbarum Species 0.000 claims description 11
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 11
- 235000015468 Lycium chinense Nutrition 0.000 claims description 11
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- 229960000984 tocofersolan Drugs 0.000 claims description 8
- 108010038807 Oligopeptides Proteins 0.000 claims description 7
- 102000015636 Oligopeptides Human genes 0.000 claims description 7
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 6
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 6
- 244000182216 Mimusops elengi Species 0.000 claims description 6
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 6
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 6
- 229940042585 tocopherol acetate Drugs 0.000 claims description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- 239000002211 L-ascorbic acid Substances 0.000 claims description 5
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 5
- 108010073771 Soybean Proteins Proteins 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 239000002076 α-tocopherol Substances 0.000 claims description 5
- 235000004835 α-tocopherol Nutrition 0.000 claims description 5
- 235000004347 Perilla Nutrition 0.000 claims description 4
- 244000124853 Perilla frutescens Species 0.000 claims description 4
- 240000008042 Zea mays Species 0.000 claims description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 4
- 235000013734 beta-carotene Nutrition 0.000 claims description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 4
- 239000011648 beta-carotene Substances 0.000 claims description 4
- 229960002747 betacarotene Drugs 0.000 claims description 4
- 235000005822 corn Nutrition 0.000 claims description 4
- 235000021323 fish oil Nutrition 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 4
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 claims description 3
- IELOKBJPULMYRW-IKTKBOKFSA-N 4-oxo-4-[[(2S)-2,5,7,8-tetramethyl-2-[(4S,8S)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl]oxy]butanoic acid Chemical compound CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(CC1)Oc(c(C)c2C)c1c(C)c2OC(CCC(O)=O)=O IELOKBJPULMYRW-IKTKBOKFSA-N 0.000 claims description 3
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims description 3
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims description 3
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims description 3
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 3
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 3
- 239000004260 Potassium ascorbate Substances 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 102000008114 Selenoproteins Human genes 0.000 claims description 3
- 108010074686 Selenoproteins Proteins 0.000 claims description 3
- 235000021307 Triticum Nutrition 0.000 claims description 3
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 3
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 3
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims description 3
- 229940114079 arachidonic acid Drugs 0.000 claims description 3
- 229940047036 calcium ascorbate Drugs 0.000 claims description 3
- 239000011692 calcium ascorbate Substances 0.000 claims description 3
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 3
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 claims description 3
- 229940017794 potassium ascorbate Drugs 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 3
- 229960005055 sodium ascorbate Drugs 0.000 claims description 3
- 239000011655 sodium selenate Substances 0.000 claims description 3
- 235000018716 sodium selenate Nutrition 0.000 claims description 3
- 229960001881 sodium selenate Drugs 0.000 claims description 3
- 239000011781 sodium selenite Substances 0.000 claims description 3
- 235000015921 sodium selenite Nutrition 0.000 claims description 3
- 229960001471 sodium selenite Drugs 0.000 claims description 3
- 235000019710 soybean protein Nutrition 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 claims description 3
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 3
- 239000004246 zinc acetate Substances 0.000 claims description 3
- 229960000314 zinc acetate Drugs 0.000 claims description 3
- 235000013904 zinc acetate Nutrition 0.000 claims description 3
- 239000011667 zinc carbonate Substances 0.000 claims description 3
- 235000004416 zinc carbonate Nutrition 0.000 claims description 3
- 229910000010 zinc carbonate Inorganic materials 0.000 claims description 3
- 229940043825 zinc carbonate Drugs 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- 229960001939 zinc chloride Drugs 0.000 claims description 3
- 239000011746 zinc citrate Substances 0.000 claims description 3
- 235000006076 zinc citrate Nutrition 0.000 claims description 3
- 229940068475 zinc citrate Drugs 0.000 claims description 3
- 239000011670 zinc gluconate Substances 0.000 claims description 3
- 235000011478 zinc gluconate Nutrition 0.000 claims description 3
- 229960000306 zinc gluconate Drugs 0.000 claims description 3
- 229940071566 zinc glycinate Drugs 0.000 claims description 3
- 239000011576 zinc lactate Substances 0.000 claims description 3
- 235000000193 zinc lactate Nutrition 0.000 claims description 3
- 229940050168 zinc lactate Drugs 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 229960001296 zinc oxide Drugs 0.000 claims description 3
- 235000014692 zinc oxide Nutrition 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- 229960001763 zinc sulfate Drugs 0.000 claims description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 3
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 claims description 3
- 241000965254 Apostichopus japonicus Species 0.000 claims description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 2
- 244000098338 Triticum aestivum Species 0.000 claims 1
- 150000002333 glycines Chemical class 0.000 claims 1
- 210000000582 semen Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- -1 oxygen radicals Chemical class 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 244000248825 Peltandra virginica Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000021095 non-nutrients Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 201000010279 papillary renal cell carcinoma Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明适用于营养食品技术领域,提供了肾癌专用型临床营养配方食品及其制备方法,配方包括优质植物蛋白质、多不饱和脂肪、维生素A、维生素C、维生素E、还原型谷胱甘肽、锌、硒、壳寡糖、雀异黄素、单宁酸、茯苓酸、海参多糖、氟尿嘧啶、枸杞子,并通过将原料消毒混合,并分装制成营养袋,针对肾癌患者饮食结构不合理、营养不均匀等不良现状,主要是通过膳食调控,补充多种维生素、矿物质、搭配药食同源和新资源食品,来改善前列腺炎患者营养结构,辅助改善机体健康状况。
Description
技术领域
本发明属于营养食品技术领域,尤其涉及肾癌专用型临床营养配方食品及其制备方法。
背景技术
肾癌又称为肾细胞癌、肾腺癌,起源于泌尿小管上皮。是泌尿生殖系统常见的恶性肿瘤,也是全球范围内十分常见的肿瘤之一,发病率占所有恶性肿瘤的3%-4%,约占肾脏恶性肿瘤的90%。每年超过20万例新发病例及10万例死亡病例,严重影响人们的生活质量,同时也加重经济负担。
肾癌分多种病理亚型,透明性肾细胞癌、乳头状肾细胞癌、嫌色细胞癌和少数具有罕见组织形态学的肾细胞癌。在肾癌亚型中,透明细胞癌是最常见的病理亚型,约占70%,其局部侵袭率、转移率、死亡率和治疗难治性率最高。肾癌早期多无症状,病变侵犯肾盂、肾盏时可表现为无痛性肉眼血尿,病变较大时伴腰痛等表现。肾癌性血尿是肾癌最常见的并发症,也是临床急症之一。30%的肾癌患者发生侵袭和转移至其他器官,常转移到骨、肺、脑和肝脏。转移性肾癌患者预后差,5年生存率低。
肾癌发病率正逐年上升。由于肾癌对化疗和放疗均不敏感,因此给肾癌的治疗带来一定的困难。因此,通过对抗癌药作用的机制深入研究,寻求较为有效的治疗方式,对肾癌的治疗起到至关重要的作用。同时还应积极开展生活方式和膳食指导,降低其发病率。
发明内容
本发明提供肾癌专用型临床营养配方食品及其制备方法,旨在补充合理平衡的饮食,改善全身的营作状态,促进患者的康复。
本发明是这样实现的,肾癌专用型临床营养配方食品,包括以下组分:优质植物蛋白质、多不饱和脂肪、维生素A、维生素C、维生素E、还原型谷胱甘肽、锌、硒、壳寡糖、雀异黄素、单宁酸、茯苓酸、海参多糖、氟尿嘧啶、枸杞子。
优选的,每一百克营养食品包括以下组分:优质植物蛋白质33.5g~58.3g、多不饱和脂肪1.5g~4g、维生素A168μg~800μg、维生素C2mg~7mg、维生素E1.5mg~5mg、还原型谷胱甘肽18mg~60mg、锌1.7mg~8.5mg、硒13μg~90μg、壳寡糖20g~30g、雀异黄素8.5μg~80μg、单宁酸1.1mg~5mg、茯苓酸8.5μg~80μg、海参多糖20g~30g、氟尿嘧啶25mg~35mg、枸杞子2g~3g。
优选的,优质植物蛋白的原料选自大豆分离蛋白、大豆肽、小麦低聚肽、玉米低聚肽粉中的一种或多种;
多不不饱和脂肪的原料选自橄榄油微囊粉、紫苏油微囊粉、二十二碳六烯酸油脂、花生四烯酸油脂、鱼油微囊粉、亚麻籽油微囊粉、茶油微囊粉中的一种或多种。
优选的,维生素A的原料选自β-胡萝卜素;
维生素C的原料选自L-抗坏血酸、L-抗坏血酸钙、L-抗坏血酸钠、L-抗坏血酸钾、维生素C磷酸酯镁、L-抗坏血酸-6-棕榈酸盐中的一种或多种;
维生素E的原料选自d-α-生育酚、dl-α-生育酚、d-α-醋酸生育酚、dl-α-醋酸生育酚、混合生育酚浓缩物、维生素E琥珀酸钙、d-α-琥珀酸生育酚、dl-α-琥珀酸生育酚中的一种或多种。
优选的,雀异黄素的原料选自大豆;
茯苓酸的原料选自茯苓;
海参多糖的原料选自海参;
氟尿嘧啶的原料选自海参。
优选的,锌的原料选自硫酸锌、葡萄糖酸锌、氧化锌、乳酸锌、柠檬酸锌、甘氨酸锌、氯化锌、乙酸锌、碳酸锌中的一种或多种;
硒的原料选自亚硒酸钠、硒酸钠、硒蛋白、富硒食用菌粉、L-硒-甲基硒代半胱氨酸、硒化卡拉胶、富硒酵母中的一种或多种。
本发明还提供肾癌专用型临床营养配方食品的制备方法,其适用于上述任意肾癌专用型临床营养配方食品,包括以下步骤:
S1、以肾癌专用型临床营养配方食品质量100克计,取优质植物蛋白质、多不饱和脂肪、维生素A、维生素C、维生素E、还原型谷胱甘肽、锌、硒、壳寡糖、雀异黄素、单宁酸、茯苓酸、海参多糖、氟尿嘧啶、枸杞子的原料分别灭菌后,均匀混合,获得混合配方;
S2、将混合配方均分为4份,形成营养袋。
与现有技术相比,本发明的有益效果是:本发明的肾癌专用型临床营养配方食品及其制备方法,配方包括优质植物蛋白质、多不饱和脂肪、维生素A、维生素C、维生素E、还原型谷胱甘肽、锌、硒、壳寡糖、雀异黄素、单宁酸、茯苓酸、海参多糖、氟尿嘧啶、枸杞子,并通过将原料消毒混合,并分装制成营养袋,针对肾癌患者饮食结构不合理、营养不均匀等不良现状,主要是通过膳食调控,补充多种维生素、矿物质、搭配药食同源和新资源食品,来改善前列腺炎患者营养结构,辅助改善机体健康状况。
附图说明
图1为本发明的肾癌专用型临床营养配方食品的制备方法的流程示意图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
实施例1
本实施例提供一种技术方案:肾癌专用型临床营养配方食品及其制备方法,配方包括以下重量份的组分:优质植物蛋白质55.92394g、多不饱和脂肪2g、维生素A500μg、维生素C5mg、维生素E3mg、还原型谷胱甘肽30mg、锌5mg、硒50μg、壳寡糖20g、雀异黄素10μg、单宁酸3mg、茯苓酸10μg、海参多糖20g、氟尿嘧啶25mg、枸杞子2g。
优质植物蛋白质来源为大豆分离蛋白、大豆肽、小麦低聚肽、玉米低聚肽粉。
增加多不饱和脂肪酸,可以改善脂代谢。多不饱和脂肪由橄榄油微囊粉、紫苏油微囊粉、二十二碳六烯酸油脂、花生四烯酸油脂、鱼油微囊粉、亚麻籽油微囊粉、茶油微囊粉。
氧自由基清除剂在肾癌治疗过程中,是通过体内抗氧化酶与内源性抗氧化剂组成的各自抗氧化作用与协同作用等多种机制有效清除氧自由基。氧自由基清除物主要有维生素A、维生素C、维生素E、还原型谷胱甘肽等。
维生素C有促进新陈代谢和解毒的作用,增强免疫功能,清除自由基,等功能。维生素C来源于L-抗坏血酸、L-抗坏血酸钙、L-抗坏血酸钠、L-抗坏血酸钾、维生素C磷酸酯镁、L-抗坏血酸-6-棕榈酸盐中的一种或多种组合。
维生素E能维持代谢器官的正常功能。维生素E来源d-α-生育酚、dl-α-生育酚、d-α-醋酸生育酚、dl-α-醋酸生育酚、混合生育酚浓缩物、维生素E琥珀酸钙、d-α-琥珀酸生育酚、dl-α-琥珀酸生育酚中的一种或多种组合。
血清硒、锌水平的降低可能是肾癌发病的危险因素。这可能与微量元素缺乏导致免疫功能降低,上皮细胞容易受到致癌物质的侵害,促进肿瘤发生。锌来源于硫酸锌、葡萄糖酸锌、氧化锌、乳酸锌、柠檬酸锌、甘氨酸锌、氯化锌、乙酸锌、碳酸锌中的一种或多种组合。硒来源于亚硒酸钠、硒酸钠、硒蛋白、富硒食用菌粉、L-硒-甲基硒代半胱氨酸、硒化卡拉胶、富硒酵母中的一种或多种组合。
壳寡糖可抑制肾转移瘤的生长,显著降低肿瘤中mRNA及其蛋白质的表达,从而抑制肿瘤血管的形成及促进肿瘤细胞的凋亡,达到抑制肿瘤生长的目的,使肿瘤饥饿致死。
雀异黄素是大豆中的一类重要的非营养素成分,可特异性抑制酪氨酸蛋白激酶。金雀异黄素对肾肿瘤细胞的作用明显。可明显抑制肾肿瘤细胞的增殖、分裂,使肿瘤细胞的增殖停滞在G1/S,G2/M期。改变细胞内细胞骨架波形蛋白的的排布方式。降低肿瘤细胞的恶性程度。本发明的雀异黄素从大豆中提取得到。
单宁酸是一类复杂的高分子多元酚类化合物,属于水解类单宁。具有多方面的药理活性,具有显著的抗炎、抗氧化、降糖、降脂、抗肿瘤等作用。单宁酸通过干预肾癌细胞氧化酶的活性,抑制蛋白分泌及靶向线粒体凋亡等机制参与抑制肾癌细胞生长及促进其凋亡。
茯苓酸是中药茯苓的有效活性物质,属于三萜类化合物,具有抗炎、抗氧化、止吐、抗癌等生物学作用。茯苓酸通过抑制Wnt信号通路的激活促进细胞凋亡,为肾癌的预防和治疗提供支持。
海参多糖是从海参中提取的天然生物来源的水溶性物质,可以抑制多种肿瘤细胞的增殖、转移,同时也有一定的肿瘤细胞杀伤作用,具有光谱、高效等优点。海参多糖通过抑制AKT/mTOR信号通路进而抑制肾癌细胞增殖,并诱导肾癌细胞发生自噬。
本发明的原料中的氟尿嘧啶从海参中提取获得。氟尿嘧啶是临床上常用的治疗消化道癌及其他实体瘤化疗药物之一。氟尿嘧啶通过抑制胸腺嘧啶核苷酸合成酶而抑制DNA的合成,同时还有抑制RNA合成的作用,产生细胞毒性进而影响细胞功能。氟尿嘧啶是一种不典型的细胞周期特异性药,它主要作用于S期,杀死处于S期的细胞,对其他细胞周期的细胞也有影响。研究显示氟尿嘧啶可以抑制食道癌细胞、胆管癌细胞、乳腺癌细胞等增殖和侵袭过程。不同浓度的氟尿嘧啶作用与肾癌细胞后,细胞增殖活性下降,侵袭和转移能力均受到抑制。
枸杞子味甘性平质润多液,入肾可益精充髓助阳,走肝能补血明目,归肺以润肺止咳,凡肝肾不足和肺肾阴虚所致诸症均可使用。枸杞子的主要成分枸杞多糖能明显提高大鼠血清中免疫球蛋白含量,促进淋巴T细胞、巨噬细胞增殖,可以增强免疫力,对机体非特异性免疫功能、细胞免疫功能、体液免疫功能均具有显著的调节作用。
制每百克肾癌专用型临床营养配方食品的原料如下:
大豆分离蛋白55.92394g、鱼油微囊粉2g、β-胡萝卜素500μg、L-抗坏血酸5mg、d-α-生育酚3mg、还原型谷胱甘肽30mg、锌5mg、硒50μg、壳寡糖20g、雀异黄素10μg、单宁酸3mg、茯苓酸10μg、海参多糖20g、氟尿嘧啶25mg、枸杞子2g。
请参阅图1,然后按照以下步骤制备肾癌专用型临床营养配方食品:
S1、以肾癌专用型临床营养配方食品质量100克计,取优质植物蛋白质、多不饱和脂肪、维生素A、维生素C、维生素E、还原型谷胱甘肽、锌、硒、壳寡糖、雀异黄素、单宁酸、茯苓酸、海参多糖、氟尿嘧啶、枸杞子的原料分别灭菌后,均匀混合,获得混合配方。
S2、将混合配方均分为4份,形成营养袋。
综上所述,本发明的肾癌专用型临床营养配方食品及其制备方法,配方包括优质植物蛋白质、多不饱和脂肪、维生素A、维生素C、维生素E、还原型谷胱甘肽、锌、硒、壳寡糖、雀异黄素、单宁酸、茯苓酸、海参多糖、氟尿嘧啶、枸杞子,并通过将原料消毒混合,并分装制成营养袋,针对肾癌患者饮食结构不合理、营养不均匀等不良现状,主要是通过膳食调控,补充多种维生素、矿物质、搭配药食同源和新资源食品,来改善前列腺炎患者营养结构,辅助改善机体健康状况。
实施例2
本实施例提供一种技术方案:肾癌专用型临床营养配方食品及其制备方法,配方包括以下重量份的组分:优质植物蛋白质55.92394g、多不饱和脂肪2g、维生素A500μg、维生素C5mg、维生素E3mg、还原型谷胱甘肽30mg、锌5mg、硒50μg、壳寡糖20g、雀异黄素10μg、单宁酸3mg、茯苓酸10μg、海参多糖20g、氟尿嘧啶25mg、枸杞子2g。
制每百克肾癌专用型临床营养配方食品的原料如下:
大豆分离蛋白25.92394g、玉米低聚肽粉30g、紫苏油微囊粉2g、β-胡萝卜素500μg、L-抗坏血酸5mg、d-α-生育酚3mg、还原型谷胱甘肽30mg、锌5mg、硒50μg、壳寡糖20g、雀异黄素10μg、单宁酸3mg、茯苓酸10μg、海参多糖20g、氟尿嘧啶25mg、枸杞子2g。
请参阅图1,然后按照以下步骤制备肾癌专用型临床营养配方食品:
S1、以肾癌专用型临床营养配方食品质量100克计,取优质植物蛋白质、多不饱和脂肪、维生素A、维生素C、维生素E、还原型谷胱甘肽、锌、硒、壳寡糖、雀异黄素、单宁酸、茯苓酸、海参多糖、氟尿嘧啶、枸杞子的原料分别灭菌后,均匀混合,获得混合配方。
S2、将混合配方均分为4份,形成营养袋。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (7)
1.肾癌专用型临床营养配方食品,其特征在于:包括以下组分:优质植物蛋白质、多不饱和脂肪、维生素A、维生素C、维生素E、还原型谷胱甘肽、锌、硒、壳寡糖、雀异黄素、单宁酸、茯苓酸、海参多糖、氟尿嘧啶、枸杞子。
2.如权利要求1所述的肾癌专用型临床营养配方食品,其特征在于:每一百克营养食品包括以下组分:优质植物蛋白质33.5g~58.3g、多不饱和脂肪1.5g~4g、维生素A168μg~800μg、维生素C2mg~7mg、维生素E1.5mg~5mg、还原型谷胱甘肽18mg~60mg、锌1.7mg~8.5mg、硒13μg~90μg、壳寡糖20g~30g、雀异黄素8.5μg~80μg、单宁酸1.1mg~5mg、茯苓酸8.5μg~80μg、海参多糖20g~30g、氟尿嘧啶25mg~35mg、枸杞子2g~3g。
3.如权利要求1所述的肾癌专用型临床营养配方食品,其特征在于:
优质植物蛋白的原料选自大豆分离蛋白、大豆肽、小麦低聚肽、玉米低聚肽粉中的一种或多种;
多不不饱和脂肪的原料选自橄榄油微囊粉、紫苏油微囊粉、二十二碳六烯酸油脂、花生四烯酸油脂、鱼油微囊粉、亚麻籽油微囊粉、茶油微囊粉中的一种或多种。
4.如权利要求1所述的肾癌专用型临床营养配方食品,其特征在于:
维生素A的原料选自β-胡萝卜素;
维生素C的原料选自L-抗坏血酸、L-抗坏血酸钙、L-抗坏血酸钠、L-抗坏血酸钾、维生素C磷酸酯镁、L-抗坏血酸-6-棕榈酸盐中的一种或多种;
维生素E的原料选自d-α-生育酚、dl-α-生育酚、d-α-醋酸生育酚、dl-α-醋酸生育酚、混合生育酚浓缩物、维生素E琥珀酸钙、d-α-琥珀酸生育酚、dl-α-琥珀酸生育酚中的一种或多种。
5.如权利要求1所述的肾癌专用型临床营养配方食品,其特征在于:
雀异黄素的原料选自大豆;
茯苓酸的原料选自茯苓;
海参多糖的原料选自海参;
氟尿嘧啶的原料选自海参。
6.如权利要求1所述的肾癌专用型临床营养配方食品,其特征在于:
锌的原料选自硫酸锌、葡萄糖酸锌、氧化锌、乳酸锌、柠檬酸锌、甘氨酸锌、氯化锌、乙酸锌、碳酸锌中的一种或多种;
硒的原料选自亚硒酸钠、硒酸钠、硒蛋白、富硒食用菌粉、L-硒-甲基硒代半胱氨酸、硒化卡拉胶、富硒酵母中的一种或多种。
7.如权利要求1至6所述的肾癌专用型临床营养配方食品的制备方法,其特征在于:包括以下步骤:
S1、以肾癌专用型临床营养配方食品质量100克计,取优质植物蛋白质、多不饱和脂肪、维生素A、维生素C、维生素E、还原型谷胱甘肽、锌、硒、壳寡糖、雀异黄素、单宁酸、茯苓酸、海参多糖、氟尿嘧啶、枸杞子的原料分别灭菌后,均匀混合,获得混合配方;
S2、将混合配方均分为4份,形成营养袋。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010538786.8A CN111642750A (zh) | 2020-06-13 | 2020-06-13 | 肾癌专用型临床营养配方食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010538786.8A CN111642750A (zh) | 2020-06-13 | 2020-06-13 | 肾癌专用型临床营养配方食品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111642750A true CN111642750A (zh) | 2020-09-11 |
Family
ID=72341626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010538786.8A Pending CN111642750A (zh) | 2020-06-13 | 2020-06-13 | 肾癌专用型临床营养配方食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111642750A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103156168A (zh) * | 2011-12-09 | 2013-06-19 | 李赣平 | 海参枸杞饮料的制作方法 |
CN103461756A (zh) * | 2013-08-29 | 2013-12-25 | 山东卫康生物医药科技有限公司 | 一种供癌症患者食用的五谷杂粮全营养配方食品 |
CN104623417A (zh) * | 2015-02-10 | 2015-05-20 | 管海涛 | 提高肿瘤患者术后免疫功能的营养药膳及制法 |
CN106473153A (zh) * | 2016-09-21 | 2017-03-08 | 河南汇博医疗股份有限公司 | 全营养配方食品及其制备方法 |
CN107319524A (zh) * | 2017-06-29 | 2017-11-07 | 上海复旦奥医医学科技有限公司 | 一种肾病专用型临床营养配方及其制备方法 |
CN110226744A (zh) * | 2019-07-05 | 2019-09-13 | 上海奥医生物医药科技有限公司 | 一种前列腺炎专用型临床营养配方及其制备方法 |
CN110800997A (zh) * | 2019-11-07 | 2020-02-18 | 上海复旦奥医医学科技有限公司 | 一种甲状腺癌专用型临床营养配方及其制备方法 |
-
2020
- 2020-06-13 CN CN202010538786.8A patent/CN111642750A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103156168A (zh) * | 2011-12-09 | 2013-06-19 | 李赣平 | 海参枸杞饮料的制作方法 |
CN103461756A (zh) * | 2013-08-29 | 2013-12-25 | 山东卫康生物医药科技有限公司 | 一种供癌症患者食用的五谷杂粮全营养配方食品 |
CN104623417A (zh) * | 2015-02-10 | 2015-05-20 | 管海涛 | 提高肿瘤患者术后免疫功能的营养药膳及制法 |
CN106473153A (zh) * | 2016-09-21 | 2017-03-08 | 河南汇博医疗股份有限公司 | 全营养配方食品及其制备方法 |
CN107319524A (zh) * | 2017-06-29 | 2017-11-07 | 上海复旦奥医医学科技有限公司 | 一种肾病专用型临床营养配方及其制备方法 |
CN110226744A (zh) * | 2019-07-05 | 2019-09-13 | 上海奥医生物医药科技有限公司 | 一种前列腺炎专用型临床营养配方及其制备方法 |
CN110800997A (zh) * | 2019-11-07 | 2020-02-18 | 上海复旦奥医医学科技有限公司 | 一种甲状腺癌专用型临床营养配方及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102402485B1 (ko) | 암 방사선요법을 향상시키기 위한 조성물 및 방법 | |
Tang et al. | Effects of heme iron enriched peptide on iron deficiency anemia in rats | |
Deruelle et al. | Vitamin C: is supplementation necessary for optimal health? | |
CN108719977A (zh) | 一种乳腺癌营养食品及其制备方法 | |
CN111436601A (zh) | 一种胰腺癌专用型临床营养配方及其制备 | |
CN110101088A (zh) | 用于妊娠糖尿病防治的精准营养代餐组合物及其使用方法 | |
KR101896024B1 (ko) | 가르시니아 캄보지아 추출물을 활용한 기능성 식품 조성물 및 이의 제조방법 | |
CN108936595A (zh) | 结肠癌营养食品及其制备方法 | |
Chi et al. | Selenium-rich royal jelly inhibits hepatocellular carcinoma through PI3K/AKT and VEGF pathways in H22 tumor-bearing mice | |
CN111513333A (zh) | 肺癌专用型临床营养配方食品及其制备方法 | |
CN102318821A (zh) | 适用于准备生育的男士的特膳营养食品 | |
CN110742267A (zh) | 一种炎性肠病全营养配方食品 | |
Barone et al. | JNK pathway and heat shock response mediate the survival of C26 colon carcinoma bearing mice fed with the mushroom Pleurotus eryngii var. eryngii without affecting tumor growth or cachexia | |
CN105796608A (zh) | 复方富勒烯保健饮用水及其制备方法 | |
CN111642750A (zh) | 肾癌专用型临床营养配方食品及其制备方法 | |
CN108936597A (zh) | 一种直肠癌营养食品及其制备方法 | |
CN114868890A (zh) | 一种适用肿瘤患者多维营养素配方 | |
KR20200043555A (ko) | 다이어트용 보조식품 조성물 | |
CN110742266B (zh) | 一种辅助调节肠道免疫功能的全营养配方食品 | |
CN108887561A (zh) | 一种具有降血脂降血糖功效的代餐粉配方 | |
Katimba et al. | Zinc Absorption & Homeostasis in the Human Body: A General Overview | |
CA2399063C (en) | A method for maintaining or improving the synthesis of mucins | |
CN103478718A (zh) | 提高人体内谷胱甘肽浓度的功能食品及其制备方法 | |
CN108813576A (zh) | 一种胃癌营养食品及其制备方法 | |
Khalua et al. | Kiwifruit and its Medicinal Properties: A Review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200911 |